PowerShares Dynamic Pharmaceuticals ETF News

A smart beta exchange traded fund, the Invesco Pharmaceuticals ETF (PJP) debuted on 06/23/2005, and offers broad exposure to the Health Care ETFs category of the market.

The Invesco Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity mark

Invesco Dynamic Pharmaceuticals ETF is a passively managed fund that tracks the Dynamic Pharmaceutical Intellidex Index. Investing in the pharmaceutical industry is challenging due to the need for spe

The Invesco Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs re

The Invesco Pharmaceuticals ETF (PJP) made its debut on 06/23/2005, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the Invesco Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund launched on 06/23/2005.

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

A smart beta exchange traded fund, the Invesco Pharmaceuticals ETF (PJP) debuted on 06/23/2005, and offers broad exposure to the Health Care ETFs category of the market.

Healthcare, the second-largest sector allocation in the S&P 500, is often viewed through the lens of defensive and value traits. The latter scenario is being amplified this year, as the S&P 500 Health

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the Invesco Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund launched on 06/23/2005.

Bank of America expects the Gilead Sciences to jump about 30%, as quoted on CNBC.

A total of nine funds launched during the week ending Sept. 1, thus a dip after the 17 ETF launches last week but not unusual in the leadup to a holiday weekend.

President Joe Biden on Tuesday pledged to “keep standing up to Big Pharma,” as he celebrated his administration's rollout of the first 10 drugs to be selected for a price-negotiation program.

Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.